Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,176,696 shares of the medical equipment provider’s stock after selling 532,674 shares during the quarter. American Century Companies Inc.’s holdings in Zimmer Biomet were worth $509,905,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Key Financial Inc raised its holdings in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. increased its position in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the period. Root Financial Partners LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth $31,000. Cary Street Partners Investment Advisory LLC lifted its position in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares during the period. Finally, Mather Group LLC. purchased a new stake in Zimmer Biomet during the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of several research analyst reports. Robert W. Baird restated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Stifel Nicolaus set a $110.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, November 5th. The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research note on Friday, January 9th. Finally, Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $98.42 on Friday. The stock has a market capitalization of $19.25 billion, a P/E ratio of 27.80, a P/E/G ratio of 2.06 and a beta of 0.62. The company’s fifty day moving average price is $91.52 and its 200 day moving average price is $95.95. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period in the prior year, the business posted $2.31 earnings per share. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.